Tango Therapeutics, Inc. (TNGX) Profit Margins
Over the twelve months to 2026-06-30, Tango Therapeutics, Inc. (TNGX) had operating margin -253.4%, net margin -229.9%, free cash flow margin -268.1%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TNGXTango Therapeutics, Inc.Follow TNGX — free
—
Price chart with a free account
- Market cap
- 3.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 16 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating margin | -157.1% | -446.8% | -312.6% | -346.1% | -178.4% | -253.4% | |
| Net margin | -157.2% | -435.1% | -278.5% | -309.7% | -162.9% | -229.9% | |
| FCF margin | -165.7% | -469.7% | -327.2% | -314.4% | -224.3% | -268.1% |
USD billions · SEC XBRL
Tango Therapeutics, Inc. — questions
- What is Tango Therapeutics, Inc.'s operating margin?
- -253.4% over the twelve months to 2026-06-30.
- What is Tango Therapeutics, Inc.'s net profit margin?
- -229.9% over the twelve months to 2026-06-30.
Every figure on this page comes from Tango Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.